Related Experiment Videos

Predictors of minimal hepatic encephalopathy in patients with cirrhosis

Praveen Sharma1, Barjesh C Sharma

  • 1Department of Gastroenterology, G. B. Pant Hospital, New Delhi, India.

Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association
|July 10, 2010
PubMed

Insights

Minimal hepatic encephalopathy (MHE) affects 41% of cirrhotic patients. Key predictors include high Model for End-Stage Liver Disease (MELD) scores, low critical flicker frequency (CFF), and elevated venous ammonia levels.

Area of Science:

  • Hepatology
  • Neurology
  • Clinical Diagnostics

Background:

  • Minimal hepatic encephalopathy (MHE) significantly impacts daily functioning in patients with liver cirrhosis.
  • Predictors for MHE in this patient population have remained largely unevaluated.

Purpose of the Study:

  • To identify and evaluate the predictors of minimal hepatic encephalopathy (MHE) in patients diagnosed with liver cirrhosis.
  • To establish diagnostic criteria for MHE using psychometric tests, P300 auditory event-related potential (P300ERP), and critical flicker frequency (CFF).

Main Methods:

  • 200 cirrhotic patients (Child A, B, C) underwent psychometry, P300ERP, and CFF assessments.
  • MHE diagnosis was based on abnormal psychometry (>2 S.D.) and P300ERP (>2.5 S.D.).
  • Univariate and multivariate logistic regression analyses were employed to determine MHE predictors.

Main Results:

  • 41% of patients (82/200) were diagnosed with MHE.
  • Elevated Model for End-Stage Liver Disease (MELD) scores, Child-Turcotte-Pugh (CTP) scores, venous ammonia levels, and reduced critical flicker frequency (CFF) were observed in MHE patients.
  • Multivariate analysis identified MELD score (>15.5), CFF (<39 Hz), and venous ammonia level (>84.5 micromol/L) as significant predictors of MHE.

Conclusions:

  • The prevalence of MHE in cirrhotic patients was found to be 41%.
  • MELD score, CFF, and venous ammonia levels are significant predictors of MHE in cirrhotic patients.
  • These findings suggest that MELD score > 15.5, CFF < 39 Hz, and venous ammonia > 84.5 micromol/L can aid in predicting MHE.
Abstract

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...